In a report released on January 27, Naz Rahman from Maxim Group reiterated a Buy rating on Silexion Therapeutics (SLXN – Research Report), with ...

Silexion Therapeutics Corp. (NASDAQ:SLXN) released new preclinical data for SIL-204, its next-generation siRNA therapeutic ...

New preclinical findings provide validation for Silexion’s new systemic administration approach for SIL-204, demonstrating ...

Three nano-cap healthcare stocks drew massive attention from retail investors on Stocktwits Tuesday, though not all for ...

Silexion Therapeutics (SLXN) announced new preclinical data for SIL-204, its next-generation siRNA therapeutic candidate. The findings ...

The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.35 A.M. ET).In the Green Tectonic Therapeutic, Inc. (TECX) is up over ...

In a challenging year for Moringa Acquisition Corp (SLXN), the company's stock has plummeted to a 52-week low, trading at ...

SIL-204 showed synergistic efficacy with 5-fluorouracil, irinotecan and gemcitabine in preclinical models of pancreatic cancer. ZSilexion plans Phase 2/3 trials for SIL-204 in 2026 and raised $5 ...

Cayman Islands, January 15, 2025 -- Silexion Therapeutics Corp (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...